News coverage about ReWalk Robotics (NASDAQ:RWLK) has been trending somewhat positive this week, according to Accern Sentiment. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. ReWalk Robotics earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned media headlines about the medical device company an impact score of 46.4377620420864 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of ReWalk Robotics (NASDAQ:RWLK) opened at 1.525 on Friday. The firm’s 50-day moving average price is $1.57 and its 200-day moving average price is $1.56. ReWalk Robotics has a 12-month low of $1.10 and a 12-month high of $6.20. The company’s market capitalization is $33.16 million.
ReWalk Robotics (NASDAQ:RWLK) last issued its quarterly earnings results on Thursday, August 3rd. The medical device company reported ($0.29) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.06. The firm had revenue of $2.01 million for the quarter, compared to analyst estimates of $1.71 million. ReWalk Robotics had a negative net margin of 389.13% and a negative return on equity of 528.26%. ReWalk Robotics’s quarterly revenue was up 145.7% compared to the same quarter last year. During the same period last year, the company posted ($0.64) EPS. On average, analysts expect that ReWalk Robotics will post ($1.30) EPS for the current fiscal year.
A number of equities research analysts have commented on the company. Zacks Investment Research cut ReWalk Robotics from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. Oppenheimer Holdings, Inc. set a $4.00 price target on ReWalk Robotics and gave the company a “buy” rating in a report on Friday, August 4th. Finally, Canaccord Genuity decreased their price target on ReWalk Robotics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, August 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $4.63.
WARNING: “ReWalk Robotics (RWLK) Getting Somewhat Positive Media Coverage, Study Shows” was first published by BBNS and is the property of of BBNS. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://baseballnewssource.com/markets/rewalk-robotics-rwlk-getting-somewhat-positive-media-coverage-study-shows/1698524.html.
About ReWalk Robotics
ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement.
Receive News & Ratings for ReWalk Robotics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics Ltd and related companies with our FREE daily email newsletter.